Skip to content

Systematic Post-Implementation Evaluation of Stents

Systematic Post-Implementation Evaluation of Stents

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05584280
Acronym
SPECS
Enrollment
1067
Registered
2022-10-18
Start date
2022-12-06
Completion date
2023-09-15
Last updated
2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Ischemia

Brief summary

To conduct a quality assurance project to establish the differences in health care processes and cost effectiveness of having the thin-strut Orsiro stent versus the thicker strut Promus stent on the shelf (i.e. as the most accessible stent).

Detailed description

Background: Individual patient-level randomized trials have suggested that the ultrathin strut Orsiro stent is associated with a lower risk of adverse ischemic events than the thin strut Promus stent. However, there are theoretical advantages of each stent in regards to usability, delivery and radial strength. Study design: The SPECS trial is a prospective, open-label, cross-sectional, cluster randomized quality assurance project, in which cardiac catheterization laboratories (hereafter referred to as center) in Västra Götaland Sweden will participate. Each week each center will place either Orsiro or Promus in the shelf in the cath lab as the most accessible stent (their workhorse stent). The specific stent to be placed on the shelf at each center each week will be randomly decided. All patients will be treated according to local treatment guidelines and at the discretion of the interventional cardiologists, including the choice of stents. The patients will be identified via the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry. The events at will be identified and extracted from Patient registry (Socialstyrelsen), Population registry (Folkbokföringen), Causes of death registry (Socialstyrelsen). Stent usage will be monitored via SWEDEHEART and local databases (stents for which the package was opened but the stent discarded). Study population: Patients undergoing percutaneous coronary intervention (PCI) in Västra Götaland. Primary objectives: To investigate the cost-effectivess of placing either thin or thick strut stents on the shelf in the cath lab. To investigate the weekly costs associated with placing either thin or thick strut stents on the shelf in the cath lab. All outcomes will be tracked over time to assess whether greater experience with the thin strut stents results in changes in any cost differences over time. If a sufficient number of patients are treated over the course of the project, retrospective analyses may be conducted using the assigned shelf stent as an instrument for assessing the effect of thin vs. thick stents on outcomes.

Interventions

DEVICEOrsiro stent on shelf

Cluster randomization to Orsiro stent on shelf vs. control

DEVICEPromus stent on shelf

Cluster randomization to Promus stent on shelf vs. treatment

Sponsors

Vastra Gotaland Region
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients undergoing PCI at any hospital participating in the study

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Cost effectiveness ratio (percent)1 yearCost effectiveness of Orsiro compared to Promus on shelf.

Secondary

MeasureTime frameDescription
How long time did the procedure take?During the procedureProcedure time (continuous variable)
How many other stents were used?During the procedureProportion of other stents used (percent)
How many additional units were needed?During the procedureNumber of adjunct devices used
How many patients were treated?1 weekNumber of patients treated
Composite of all-cause death, myocardial infarction, or coronary revascularization1- yearCumulative risk of death, myocardial infarction, or coronary revascularization

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 30, 2026